Quick Order Cart

Cat. No. ARG43768

C5AR1 Knockout THP-1 Cell Line

  • Product Type:

    In Stock Cell Lines

  • Species:

    Homo sapiens (Human)

  • Tissue Source:

    Blood (peripheral blood)

  • Disease:

    Acute monoblastic leukemia

The C5AR1 Knockout THP-1 Cell Line is a validated CRISPR/Cas9-edited human monocytic leukemia cell line that lacks expression of the complement C5a receptor (CD88). This targeted gene disruption abolishes C5a-induced calcium signaling, chemotaxis, and production of inflammatory cytokines like IL-6 and IL-8, via blockade of downstream PI3K/AKT and MAPK pathways. It serves as a valuable model for investigating complement-mediated inflammatory diseases, monocyte/macrophage biology, and C5AR1 antagonist screening. Assays such as flow cytometry, calcium mobilization, and cytokine ELISA validate its utility in research on sepsis, rheumatoid arthritis, and atherosclerosis.

Inquire Now

In stock

Ships next business day


Ask a Question

Shipping Info:

Cryopreserved in vials and shipped on dry ice


Disclaimer:

For Research Use Only

  • Characteristics

    Host Cell

    THP-1

    Sex of Donor

    Male

    Age

    1 year

    Derived From Site

    In situ; Peripheral blood

    Gene Name

    C5AR1

    Gene Identifier

    NCBI Gene ID 728

    Growth Mode

    Suspension

    Storage

    Liquid nitrogen (LN2)

  • Culture Conditions

    Temperature

    37°C

    Atmosphere

    5% COâ‚‚

  • Quality Control

    Sterility testing

    The bacterial, yeast, and fungi are not detected in these cells by daily monitor.

    Mycoplasma testing

    Negative for mycoplasma through PCR analysis

  • Disclaimer

    Intended Use

    This product is intended for laboratory in vitro use only. It is not intended for diagnostic, therapeutic, or clinical applications.

    Disclaimer

    Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability. References to scientific literature and patents are for informational purposes only, and the customer assumes sole responsibility for verifying their accuracy.

    By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use, including compliance with all applicable safety and environmental regulations and precautions. Relevant laws, regulations, and ethical guidelines must be followed in conducting any research, modifications, or derivatives derived from this product.

    This product is provided "AS IS", and except as expressly stated herein, Ascent Research disclaims all other warranties, express or implied. Under no circumstances shall Ascent Research, its affiliates, or representatives be liable for indirect, incidental, consequential, or punitive damages arising from the use of this material. While Ascent Research employs rigorous quality control measures, we shall not be held responsible for damages resulting from misidentification or misinterpretation of the provided materials.

Description

The C5AR1 Knockout THP-1 Cell Line is a CRISPR/Cas9-edited human monocytic leukemia cell line with targeted disruption of the C5AR1 gene encoding the complement anaphylatoxin C5a receptor (CD88). This G protein-coupled receptor mediates chemotaxis, degranulation, and pro-inflammatory responses in myeloid cells. The CRISPR/Cas9-mediated gene disruption eliminates functional C5AR1 expression, providing a defined loss-of-function model for dissecting C5a-driven signaling without endogenous receptor interference.

THP-1 cells are a widely used human monocytic leukemia line originally isolated from a patient with acute monocytic leukemia (AML M5). They serve as a classic model for investigating monocyte and macrophage biology, including differentiation, immune response, and inflammatory processes. Upon phorbol ester treatment, THP-1 cells differentiate into macrophage-like cells, broadening experimental utility. Their endogenous C5AR1 expression and robust responsiveness to C5a make this knockout line particularly suitable for comparative studies of complement signaling in myeloid contexts.

C5AR1 functions as the primary receptor for the anaphylatoxin C5a, activating heterotrimeric G proteins G??i and G??q. Downstream, phospholipase C-?? generates IP3 and diacylglycerol, triggering intracellular calcium mobilization and protein kinase C activation. C5AR1 couples to the PI3K/AKT pathway and MAPK cascades, including ERK1/2 and p38 MAPK, which converge on transcription factors NF-??B and AP-1 to drive production of pro-inflammatory cytokines such as IL-6, IL-8, and TNF-??. Additionally, C5AR1 promotes actin cytoskeleton rearrangement through Rho family GTPases, facilitating chemotaxis and degranulation. The receptor interacts with ??-arrestin-1 for desensitization and internalization, and forms functional complexes with CD11b/CD18 integrin to modulate leukocyte adhesion and migration. Upstream, C5a is generated by complement C5 convertases, and receptor activation is influenced by inflammatory mediators including LPS, TNF-??, and IL-6.

In the THP-1 context, knockout of C5AR1 eliminates C5a-induced calcium mobilization, chemotactic migration, and secretion of inflammatory cytokines, confirming its essential role. This engineered cell line enables precise dissection of C5AR1-dependent and -independent pathways in monocytic cells. It is particularly valuable for exploring how complement anaphylatoxins intersect with innate immune signals, for validating the specificity of pharmacological C5a receptor antagonists, and for generating isogenic comparisons in studies of sepsis, acute lung injury, rheumatoid arthritis, and ischemia-reperfusion injury. The amenability of THP-1 cells to genetic manipulation and functional assays further supports high-throughput screening of compounds targeting complement-driven inflammation.

Key research applications include mechanistic studies of C5a-mediated signaling in monocytes and macrophages, inflammatory disease modeling, and drug discovery efforts aimed at C5AR1 blockade. The cell line is compatible with a variety of experimental techniques, such as Western blotting to confirm protein loss, flow cytometry for CD88 expression quantification, calcium mobilization assays, chemotaxis assays, and cytokine ELISAs for IL-6 and IL-8. Transcriptomic analyses via RNA-seq or RT-qPCR can reveal changes in downstream gene networks, while NF-??B reporter assays and phagocytosis assays offer functional readouts. In cancer immunology, the role of C5a in tumor-associated macrophage polarization can be explored using this model. For further information or to discuss custom applications, please contact Ascent Research.

Reset Password

    Reach Us Questions? Click Me Here!

    Fill out the form below and a member of our team will contact you shortly!

    *Required field



      Reach Us

      Fill out the form below and a member of our team will contact you shortly!

      *Required field

      Product Inquiry (Optional)